PropThink: A Fresh Look At KERX; High Odds For Zerenex Phase III Success

[ACN Newswire] – Keryx Biopharmaceuticals (NASDAQ:KERX) announced disappointing news earlier this year for its cancer compound perifosine, and the stock remains in the penalty box. However, the story is now shifting to … more

View todays social media effects on KERX

View the latest stocks trending across Twitter. Click to view dashboard